Profile of:

Deepak Jadon


I am a consultant rheumatologist, Director of the Rheumatology Research Unit, lead for psoriatic arthritis (PsA) and co-lead for axSpA at Cambridge University Hospitals. Having grown up in Cardiff, I graduated from the University of Wales College of Medicine in 2003, and then undertook clinical training in rheumatology and general internal medicine in Bath and Bristol between 2007 - 2015. I completed my PhD thesis on ‘biomarkers of psoriatic arthritis phenotypes’ at the Royal National Hospital for Rheumatic Diseases (Bath, UK) in 2015. I have particular expertise in the investigation and management of psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA) and rheumatoid arthritis (RA). I am qualified in the use of musculoskeletal ultrasound to improve diagnostic accuracy and assessment of disease activity. My research interests include genetic and serum biomarkers of PsA, AS and SpA, in particular those that predict prognosis and developing psoriatic spondyloarthritis or arthritis mutilans. I have researched the clinical and radiographic differences between PsA and AS, and juvenile- vs. adult-onset AS. As Director of the Rheumatology Research Unit, I lead on >10 phase 2a – 4 clinical studies of novel therapeutic agents for PsA, AS and RA. The research unit currently has >20 active clinical trials including in addition SLE, Sjogren's, GCA, PMR, gout, and chronic pain. I have particular expertise in existing and emerging biologics (biologicals such TNFi, IL-17i, IL-23i, JAKi, PDE4i) and biosimilars therapies, both in clinical practice and clinical trials. As an Associate-PI at the University of Cambridge, my research interests include biomarkers (genetic, serum, cellular, MRI, ultrasound and radiographic) of psoriatic arthritis and ankylosing spondylitis; in terms of disease severity, phenotype and treatment response. In October 2020, I was appointed Director of Studies At Emmanuel College, University of Cambridge.

Full name: Deepak Jadon

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 51

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease (2023)
https://pubmed.ncbi.nlm.nih.gov/37632666/

Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting (2023)
https://pubmed.ncbi.nlm.nih.gov/37527862/

Proceedings of the GRAPPA 2022 Executive Retreat (2023)
https://pubmed.ncbi.nlm.nih.gov/37527861/

Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis (2023)
https://pubmed.ncbi.nlm.nih.gov/36963796/

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations (2023)
https://pubmed.ncbi.nlm.nih.gov/36455946/

Horizon scan: State-of-the-art therapeutics for psoriatic arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/36567224/

The role of the multidisciplinary team in the management of psoriatic arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/36356109/

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (2022)
https://pubmed.ncbi.nlm.nih.gov/35761070/

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs (2022)
https://www.asas-group.org/profile/

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling (2022)
https://pubmed.ncbi.nlm.nih.gov/35507331/

Axial involvement in psoriatic arthritis: An update for rheumatologists (2021)
https://pubmed.ncbi.nlm.nih.gov/34198146/

Unmet needs in psoriatic arthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34099367/

Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study (2021)
https://pubmed.ncbi.nlm.nih.gov/34074666/

Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study (2021)
https://pubmed.ncbi.nlm.nih.gov/34074665/

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting (2021)
https://pubmed.ncbi.nlm.nih.gov/34074658/

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review (2021)
https://pubmed.ncbi.nlm.nih.gov/33995606/

A comparison of clinical examination and ultrasound enthesitis indices in patients with psoriatic arthritis, adjusted for concomitant fibromyalgia (2021)
https://pubmed.ncbi.nlm.nih.gov/33854573/

Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review (2021)
https://pubmed.ncbi.nlm.nih.gov/33786068/

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design (2021)
https://pubmed.ncbi.nlm.nih.gov/33663566/

Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study (2021)
https://pubmed.ncbi.nlm.nih.gov/33649075/

Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study (2021)
https://pubmed.ncbi.nlm.nih.gov/33649073/

Multidisciplinary working in the management of axial and peripheral spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/33354231/

Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management (2020)
https://pubmed.ncbi.nlm.nih.gov/33224281/

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope (2020)
https://pubmed.ncbi.nlm.nih.gov/33097948/

Applying precision medicine to unmet clinical needs in psoriatic disease (2020)
https://pubmed.ncbi.nlm.nih.gov/33024296/

Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting (2020)
https://pubmed.ncbi.nlm.nih.gov/32482764/

Human osteoarthritic synovial fluid increases excitability of mouse dorsal root ganglion sensory neurons: an in-vitro translational model to study arthritic pain (2020)
https://pubmed.ncbi.nlm.nih.gov/31410487/

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting (2020)
https://pubmed.ncbi.nlm.nih.gov/33589562/

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting (2019)
https://pubmed.ncbi.nlm.nih.gov/31154399/

Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study (2019)
https://pubmed.ncbi.nlm.nih.gov/30824637/

Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/30247726/

Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation (2018)
https://pubmed.ncbi.nlm.nih.gov/30244217/

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting (2018)
https://pubmed.ncbi.nlm.nih.gov/29858357/

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database (2018)
https://pubmed.ncbi.nlm.nih.gov/29858349/

Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis (2018)
https://pubmed.ncbi.nlm.nih.gov/29077973/

Th17 cell responses in spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/30509440/

Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study (2017)
https://pubmed.ncbi.nlm.nih.gov/28934972/

A rare coding allele in IFIH1 is protective for psoriatic arthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28501801/

Proceedings of the GRAPPA 2016 Retreat (2017)
https://pubmed.ncbi.nlm.nih.gov/28461522/

Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/27913376/

Implications of the diversity of class I HLA associations in psoriatic arthritis (2016)
https://pubmed.ncbi.nlm.nih.gov/27455857/

Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study (2016)
https://pubmed.ncbi.nlm.nih.gov/26773116/

Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History (2015)
https://pubmed.ncbi.nlm.nih.gov/25979723/

Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy (2015)
https://pubmed.ncbi.nlm.nih.gov/25362660/

Clinical outcomes and progression to orthopedic surgery in juvenile- versus adult-onset ankylosing spondylitis (2015)
https://pubmed.ncbi.nlm.nih.gov/25331747/

Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis (2014)
https://pubmed.ncbi.nlm.nih.gov/23925955/

Juvenile versus adult-onset ankylosing spondylitis — clinical, radiographic, and social outcomes. a systematic review (2013)
https://pubmed.ncbi.nlm.nih.gov/24037547/

Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis (2013)
https://pubmed.ncbi.nlm.nih.gov/23291384/

Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis (2013)
https://pubmed.ncbi.nlm.nih.gov/23093722/

The ClASsification for Psoriatic ARthritis (CASPAR) criteria–a retrospective feasibility, sensitivity, and specificity study (2012)
https://pubmed.ncbi.nlm.nih.gov/22089469/

Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas (2005)
https://pubmed.ncbi.nlm.nih.gov/15963057/